Premium
THIS ARTICLE HAS BEEN RETRACTED: An Australian Experience With the Molecular Adsorbents Recirculating System (MARS)
Author(s) -
Kurtovic Jelica,
Boyle Martin,
Bihari David,
Riordan Stephen M
Publication year - 2006
Publication title -
therapeutic apheresis and dialysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.415
H-Index - 53
eISSN - 1744-9987
pISSN - 1744-9979
DOI - 10.1111/j.1744-9987.2006.00338.x
Subject(s) - medicine , sepsis , indocyanine green , liver function , hepatic encephalopathy , liver disease , organ dysfunction , gastroenterology , intensive care unit , liver function tests , extracorporeal , intensive care medicine , surgery , cirrhosis
Abstract: The molecular adsorbents recirculating system (MARS) is a form of artificial extracorporeal liver support which has the potential to remove substantial quantities of albumin‐bound toxins postulated to contribute to the pathogenesis of liver cell damage, hemodynamic instability and multi‐organ failure in patients with acute liver failure and acute‐on‐chronic liver failure (AoCLF). We assessed the efficacy of MARS therapy in a cohort of patients with severe liver damage unresponsive to intensive medical therapy. MARS therapy was instituted late in the clinical course of six patients with severely impaired liver function refractory to intensive medical therapy, including four with AoCLF precipitated by sepsis and two with liver dysfunction due to sepsis in the absence of pre‐existing chronic liver disease. Outcome measures included markers of hemodynamic stability, renal function, serum bilirubin and bile acid levels, arterial ammonia levels, the arterial ketone body (acetoacetate/β‐hydroxybutyrate) ratio, hepatic encephalopathy grade and the plasma disappearance rate of indocyanine green. The rates of discharge from the intensive care unit and in‐hospital mortality were determined. Our findings suggest that MARS treatment might be associated with some clinical efficacy even in patients with advanced multi‐organ dysfunction occurring in the setting of severe liver damage and in whom treatment is instituted late in the clinical course. However, the overall survival rate (1/6; 17%) was poor. More data obtained from larger cohorts of patients enrolled in randomized controlled studies will be required in order to identify categories of liver failure patients who might benefit most from MARS treatment and to ascertain the most appropriate timing of intervention.